Evaluation of statistical designs in phase i expansion cohorts: The Dana-Farber/Harvard cancer center experience

Journal of the National Cancer Institute

Volumn 106, Issue 7, 2014, Pages

  Dahlberg, Suzanne E ^a   Shapiro, Geoffrey I ^b   Clark, Jeffrey W ^c,d   Johnson, Bruce E ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Department of Hematology and Oncology ^*  (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CENTER; CANCER RESEARCH; CLINICAL PROTOCOL; CLINICAL RESEARCH; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ACADEMIC MEDICAL CENTERS; BIOSTATISTICS; BOSTON; CANCER CARE FACILITIES; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; HUMANS; SAMPLE SIZE;

EID: 84905216493     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju163     Document Type: Article

References (47)

1. Storer BE. An evaluation of phase I clinical trials designs in the continuous dose-response setting. Stat Med. 2001;20(16):2399-2408.
2. Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45(3):925-937.
3. Rogatko A, Schoeneck D, Jonas W, et al. Translation of innovative designs into phase I trials. J Clin Oncol. 2007;25(31):4982-4986.
4. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708-720.
5. Ji Y, Li Y, Nebiyou B. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials. 2007;4(3):235-244.
6. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics. 1990;46(1):33-48.
7. Rubenstein LV, Simon RM. Phase I clinical trial design. In Budman DR, Calvert AH, Rowinsky EK, eds. Handbook of Anticancer Drug Development. Amsterdam: Elsevier; 2003:297-308.
8. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics. 1998;54(1):251-264.
9. Gatsonis C, Greenhouse JB. Bayesian methods for phase I clinical trials. Stat Med. 1992;11(10):1377-1389.
10. Mick R, Ratain MJ. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993;85(3):217-223.
11. Ji Y, Wang S-J. Modified toxicity probability interval design: A safer and more reliable method than the 3+3 design for practical phase I trials. J Clin Oncol. 2013;31(14):1785-1796.
12. Gordon NH, Willson JK. Using toxicity grades in the design and analysis of cancer phase I clinical trials. Stat Med. 1992;11(16):2063-2075.
13. Bolognese JA. A Monte Carlo comparison of three up-and-down designs for dose ranging. Control Clin Trials. 1983;4(3):187-196.
14. Edler L. Statistical requirements of phase I studies. Onkologie. 1990;13(2):90-95.
15. Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50(4):219-244.
16. Penta JS, Rosner GL, Trump DL. Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother Pharmacol. 1992;31(3):247-250.
17. Collins JM, Zaharko DS, Dedrick RL, et al. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986;70(1):73-80.
18. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst. 1990;82(16):1321-1326.
19. Geller NL. Design of phase I and II clinical trials in cancer: A statistician's view. Cancer Invest. 1984;2(6):483-491.
20. Ivy SP, Siu LL, Garrett-Mayer E, et al. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: A report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010;16(6):1726-1736.
21. American Society of Clinical Oncology. Critical role of phase I clinical trials in cancer treatment. J Clin Oncol. 1997;15(2):853-859.
22. Ratain MJ, Mick R, Schilsky RL, et al. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993;85(20):1637-1643.
23. Dowlati A, Manda S, Gibbons J, et al. Multi-institutional phase I trials of anticancer agents. J Clin Oncol. 2008;26(12):1926-1931.
24. Iasonos A and O'Quigley J. Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol. 2013;31(31):4014-4021.
25. Manji A, Brana I, Amir E, et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in singleagent phase I cancer trials. J Clin Oncol. 2013;31(33):4260-4267.
26. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
27. Muggeo VMR. Estimating regression models with unknown break-points. Stat Med. 2003;22(19):3055-3071.
28. Muggeo VMR. Segmented: An R package to fit regression models with broken-line relationships. R News. 2008;8(1):20-25.
29. Davies RB. Hypothesis testing when a nuisance parameter is present only under the alternative. Biometrika.1987;74(1):33-43.
30. Jones CW, Handler L, Crowell KE. Non-publication of large randomized clinical trials: cross sectional analysis. BMJ. 2013;347:f6104.
31. Smith TL, Lee JJ, Kantarjian HM, et al. Design and results of phase I cancer clinical trial: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996;14(1):287-295.
32. Overman MJ, Modak J, Kopetz S, et al. Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J Clin Oncol. 2013;31(1):17-22.
33. Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol. 2006;24(19):2987-2990.
34. Agrawal M, Emanuel EJ. Ethics of phase I oncology studies: reexamining the arguments and data. JAMA. 2003;290(8):1075-1082.
35. Camacho LH, Bacik J, Cheumg A, et al. Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer. 2005;104(7):1497-1504.
36. Miller FG, Joffe S. Phase I oncology trials and informed consent. J Med Ethics. 2013;39(12):761-764.
37. Brahmer JR, Horn L, Antonia S, et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol. 2012;30(Suppl):abstract 7509.
38. Hodi FS, Sznol M, McDermott DF, et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). J Clin Oncol. 2012;30(Suppl):abstract 8507.
39. McDermott DF, Drake CG, Sznol M, et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2012;30(Suppl):abst ract 4505.
40. Topalian SL, Brahmer JR, Hodi FS, et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. J Clin Oncol. 2012;30(Suppl):abstract CRA2509.
41. Tykodi SS, Brahmer JR, Hwu W-J, et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J Clin Oncol. 2012;30(Suppl):abstract 2510.
42. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-1042.
43. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
44. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500.
45. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
46. Wetterstrand KA. DNA sequencing costs: data from the NHGRI Large-Scale Genome Sequencing Program. http://www.genome.gov/sequencingcosts/. Accessed May 23, 2014.
47. Metzker M. Sequencing technologies\-The next generation. Nat Rev Genet. 2010;11(1):31-46